20% Of World's Leading Drugs In 1992 "Of UK Origin"

3 September 1995

Products of UK origin represented about 19% of the world's leading group of drugs in 1992 and about 26% by sales volume, reports the UK-based Centre for Medicines Research.

The average sales per medicine, at $796 million, is higher than any other country, it says. In only three countries do sales exceed the values of their relative domestic markets, and in the UK this is by a ratio of nearly three times, putting it in second place behind Switzerland. And, although the UK represents only 4% of the free world market for prescription drugs, UK-owned companies originated one-fifth of the leading products in 1992.

However, the CMR says the consistent ratio which it has found between sales and R&D expenditure suggests that pressure from price reforms and cost containment will have direct repercussions on the extent of R&D, forecasting that industry growth during the 1990s will be much reduced to only around 7%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight